Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases and neuro-ophthalmic disorders. The company's lead product candidate, zervimesine (CT1812), is an oral small-molecule therapy designed to protect brain synapses and restore normal cellular functions. The company is advancing zervimesine through Phase 2 clinical studies for Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy secondary to dry age-related macular degeneration.
Cognition Therapeutics is publicly traded
IPO'd on October 8, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under CGTX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2007
Employees
25–35
Total Funding
$157.5M
1 rounds
Total raised $157.5M across 1 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-08-2026
Latest Round
Type
IPO
Date
October 8, 2021
Amount
$45.2M
Valuation
$0.26B
Lisa Ricciardi
Chief Executive Officer
Susan Catalano
Chief Science Officer and Co-Founder
Gilbert Rishton
Co-Founder and Chief Chemistry Advisor
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Eli Lilly
Developing donanemab (Kisunla), an anti-amyloid monoclonal antibody approved by FDA for early symptomatic Alzheimer's disease with shorter, less frequent infusions.
Biogen/Eisai
Developing lecanemab (Leqembi), the first disease-modifying therapy approved for early symptomatic Alzheimer's disease (FDA approval July 2023).
Roche/AC Immune
Developing anti-tau and anti-amyloid therapies for neurodegenerative diseases including Alzheimer's disease.
Yes, Cognition Therapeutics is publicly traded under the ticker symbol CGTX on the NASDAQ. The company went public in October 8, 2021.
Cognition Therapeutics trades under the ticker symbol CGTX on the NASDAQ. It began trading in October 8, 2021.
Cognition Therapeutics (CGTX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CGTX to place an order.
Cognition Therapeutics went public in October 8, 2021 via ipo. Cognition Therapeutics commenced trading on NASDAQ under ticker CGTX on October 8, 2021 at $12.00 per share IPO price. The company is a public, trading biopharmaceutical company with its lead product zervimesine in Phase 2 clinical development.
Cognition Therapeutics raised $157.5M across 1 disclosed funding rounds prior to its public listing.
Cognition Therapeutics was co-founded by Susan Catalano, and Gilbert Rishton in 2007.
Cognition Therapeutics is headquartered in Pittsburgh, PA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.